Prevalence of Anti-HLA Antibodies in Multiply Transfused Patients with Hematologic Malignancy
Issued Date
2023-01-01
Resource Type
ISSN
01252208
Scopus ID
2-s2.0-85179603548
Journal Title
Journal of the Medical Association of Thailand
Volume
106
Issue
11
Start Page
1049
End Page
1054
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand Vol.106 No.11 (2023) , 1049-1054
Suggested Citation
Yeampinij M., Vejbaesya S., Khuhapinant A., Luangtrakool P. Prevalence of Anti-HLA Antibodies in Multiply Transfused Patients with Hematologic Malignancy. Journal of the Medical Association of Thailand Vol.106 No.11 (2023) , 1049-1054. 1054. doi:10.35755/jmedassocthai.2023.11.13913 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/95628
Title
Prevalence of Anti-HLA Antibodies in Multiply Transfused Patients with Hematologic Malignancy
Author's Affiliation
Corresponding Author(s)
Other Contributor(s)
Abstract
Background: Human leukocyte antigen (HLA) alloimmunization can be induced by exposure to non-self HLA molecules, such as foreign tissue during transplantation, pregnancy, and blood products. Antibodies against HLA lead to serious complications in patients receiving blood transfusions. Objective: The present study aimed to determine the prevalence and risk factors for HLA alloimmunization in multiple transfused patients with hematologic malignancies at Siriraj Hospital. Materials and Methods: The present research was a cross-sectional study. The samples comprised 100 cases of hematologic malignancy patients who had a history of at least three episodes of transfusion with cellular blood components. All patients were tested for anti-HLA class I and class II antibodies by Luminex assay. Results: The overall prevalence of HLA alloimmunization in multiple transfused patients with hematologic malignancies was 40%. Anti-HLA class I, class II, and both class I and class II antibodies were detected in 35%, 30%, and 25% of the patients, respectively. Factors related to the development of anti-HLA antibodies were previous pregnancy (OR 4.82, 95% CI 1.62 to 14.35, p=0.005), five or more transfusions (OR 7.82, 95% CI 2.22 to 27.55, p=0.001), and diagnoses with myelodysplastic syndromes (MDS) antibodies (OR 5.88, 95% CI 1.98 to 17.47, p=0.001). Conclusion: Patients with hematologic malignancies who required long-term blood transfusion support could be at high risk for the development of anti-HLA antibodies. Important risk factors are pregnancy, multiple transfusions, and MDS.